Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
Michael W StewartCollege of Medicine, Mayo Clinic, Jacksonville, FL, USAAbstract: Age-related macular degeneration (AMD) has become a major public health problem and a leading cause of blindness in industrialized nations. AMD results from the ageing eye's inability to metabolize and disp...
Guardado en:
Autor principal: | Stewart MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b3d749c910ee414997212020ae887f00 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas M, et al.
Publicado: (2013) -
Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration
por: Keles S, et al.
Publicado: (2014) -
Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives
por: Neffendorf JE, et al.
Publicado: (2015) -
Treatment of age-related macular degeneration: focus on ranibizumab
por: Martin S Spitzer, et al.
Publicado: (2008) -
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
por: Dervenis N, et al.
Publicado: (2016)